GLP-1RA Therapy Recovers Vascular Regenerative Cell Content in High Cardiovascular-Risk Individuals with Type 2 Diabetes

被引：0
|
作者：
Krishnaraj, Aishwarya
Park, Brady
Bakbak, Ehab
Verma, Raj
Quan, Adrian
Teoh, Hwee
Hess, David A.
Verma, Subodh
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-755-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
755-P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] GLP-1RA therapy increases circulating vascular regenerative cell content in people living with type 2 diabetes
    Park, Brady
    Krishnaraj, Aishwarya
    Teoh, Hwee
    Bakbak, Ehab
    Dennis, Fallon
    Quan, Adrian
    Hess, David A.
    Verma, Subodh
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2024, 327 (02): : H370 - H376
  • [2] Cardiovascular benefits of GLP-1RA and SGLT-2i in women with type 2 diabetes
    Mishriky, Basem M.
    Cummings, Doyle M.
    Powell, James R.
    PRIMARY CARE DIABETES, 2022, 16 (03) : 471 - 473
  • [3] Eliminating exogenous insulin therapy in patients with type 2 diabetes by duodenal ablation and GLP-1RA decreases risk scores for cardiovascular events
    Meiring, S.
    Busch, C. B. E.
    van Baar, A. C. G.
    Hemke, R.
    Holleman, F.
    Nieuwdorp, M.
    Bergman, J. J. G. H. M.
    CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [4] Eliminating exogenous insulin therapy in patients with type 2 diabetes by duodenal ablation and GLP-1RA decreases risk scores for cardiovascular events
    S. Meiring
    C. B. E. Busch
    A. C. G. van Baar
    R. Hemke
    F. Holleman
    M. Nieuwdorp
    J. J. G. H. M. Bergman
    Cardiovascular Diabetology, 21
  • [5] Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy
    Dave, Chintan V.
    Kim, Seoyoung C.
    Goldfine, Allison B.
    Glynn, Robert J.
    Tong, Angela
    Patorno, Elisabetta
    CIRCULATION, 2021, 143 (08) : 770 - 779
  • [6] Glycaemic control and beta cell function in type 2 diabetes on SGLT2i and GLP-1RA combination therapy
    Martinez, R.
    Al-Jobory, H.
    Adams, J.
    Chavez-Velasquez, A.
    Triplitt, C.
    DeFronzo, R. A.
    Cersosimo, E.
    DIABETOLOGIA, 2017, 60 : S408 - S409
  • [7] Finerenone in patients across the spectrum of CKD and type 2 diabetes by GLP-1RA use
    Caramori, M. L.
    Rossing, P.
    Anker, S.
    Filippatos, G.
    Pitt, B.
    Fonseca, V.
    Umpierrez, G. E.
    Lambelet, M.
    Viswanathan, P.
    Lawatscheck, R.
    Joseph, A.
    Bakris, G.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S304 - S304
  • [8] Disparities in GLP-1RA Prescription Among a Registry of Patients With Type 2 Diabetes and ASCVD
    Kashyap, Sangeeta
    Avanetti, Eleonora
    Gullapelli, Rakesh
    Nasir, Khurram
    Sadhu, Archana
    OBESITY, 2024, 32 : 151 - 151
  • [9] The Difference in the Effects on Microalbuminuria Depending on the Order of GLP-1RA and SGLT2i Therapy in Type 2 Diabetes
    Ohara, Masaya
    Motoyama, Koka
    Tamai, Anna
    Sakura, Takeshi
    Yakushiji, Yosuke
    Hosoi, Masayuki
    DIABETES, 2019, 68
  • [10] Risk of Cardiovascular Outcomes in Diabetes Patients following the Addition of SGLT2 Inhibitors vs. Sulfonylureas to Baseline GLP-1RA Therapy
    Dave, Chintan
    Kim, Seoyoung C.
    Goldfine, Allison
    Glynn, Robert
    Patorno, Elisabetta
    DIABETES, 2020, 69
12345